Key Highlights

  • ImmunityBio (NASDAQ:IBRX) fell about 20% on November 9, 2026 to around USD 6.89, from a close of USD 8.64 the previous Friday, with more than twice its average Volume changing hands.
  • Third-quarter net product Revenue from Anktiva rose 53% to USD 48.7 million, but total revenue of about USD 48.8 million fell short of expectations near USD 59.2 million.
  • The quarter ended a run of eight consecutive quarters of sequential growth, coming in below the record USD 50.7 million reported in the second quarter.
  • The net loss widened to USD 184.6 million, including a USD 77.9 million non-cash charge tied to the Fair Value of a related-party convertible note and warrants, and cash stood at USD 334.3 million.

What Drove the Selloff

The drop in ImmunityBio (NASDAQ:IBRX) was about direction, not growth. Year-over-year sales were strong, but investors had priced in continued quarter-on-quarter increases after a long run of sequential gains and a stock that had risen about 300% over the past year. A sequential decline from USD 50.7 million to USD 48.7 million, against expectations for a step up toward USD 59 million, suggested that the commercial ramp of Anktiva in bladder cancer may be uneven. Momentum-driven holders sold quickly, and the size of the move reflected how far expectations had run ahead of results. The headline net loss was also much larger than a year earlier, though most of the increase came from a non-cash accounting charge linked to the higher share price rather than from operating spending. Research and Development spending rose to USD 71.5 million and selling, general and administrative costs to USD 54.0 million as the company expands commercial operations.

The Positives in the Release

The quarter included meaningful clinical and regulatory progress. In the QUILT-2.005 study, Cohort A, covering 370 patients with BCG-naive high-grade non-muscle invasive bladder cancer, met its primary endpoint for Anktiva plus BCG against BCG alone, and the company plans a supplemental filing in the fourth quarter of 2026. In October, the FDA expanded the label to cover more BCG-unresponsive patients, including those with high-grade papillary-only tumours. The drug also won approval in Israel through a local partner, and the first patients in Europe were treated on November 4. Long-term data published in October showed 84% of patients avoided bladder removal at 36 months. Nine-month product revenue of USD 143.6 million is already well above the USD 113.0 million recorded for all of 2025. Management said more physicians are prescribing Anktiva to multiple patients, a sign of growing familiarity with the therapy.

Risks and What to Watch

The key risk is that quarterly sales remain lumpy as Anktiva moves into wider use, which would keep the stock volatile. ImmunityBio (NASDAQ:IBRX) also continues to post heavy losses, and while USD 334.3 million in cash and investments provides a cushion, further Capital raising cannot be ruled out if spending stays high. Supply of BCG, which is used alongside Anktiva, has been limited in the past and could constrain growth. Investors should watch fourth-quarter product revenue for a return to sequential growth, the timing and outcome of the planned filing based on the BCG-naive data, the pace of launches in Europe and other markets, and any further changes to the convertible note and Warrant liabilities.

Where Things Stand

ImmunityBio fell about 20% on November 9, 2026 because third-quarter Anktiva sales of USD 48.7 million, while up 53% from a year ago, slipped from the prior quarter and missed expectations. Clinical progress was strong, including a positive Phase 3 cohort and new approvals. The next quarter's sales trend will decide whether the drop was an overreaction.